Patients with stage IV small-cell lung cancer lived longer when given the immunotherapy atezolizumab with chemotherapy, setting the stage for what could become the first new treatment approved in decades for this particularly aggressive form of lung cancer.

Los Angeles native Christina Shaw had two powerful goals when she decided to move cross country to live in Nashville – the first was to support her favorite hockey team and the second was to meet a renowned lung cancer specialist at Vanderbilt-Ingram Cancer Center.

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has received a 2015 Cancer Clinical Investigator Team Leadership Award (CCITLA) from the National Cancer Institute (NCI).

Providing increased mentorship, research opportunities and a nurturing, intellectual environment during fellowship training may help reduce a projected shortage of academic hematologists and oncologists.